phase 2a dose escalation study to investigate the safety, PK, PD, and efficacy of CC-220 in patients with SLE. Forty-two (42) adult SLE subjects fulfilling SLE ACR criteria, having a history of SLE for ≥6 months and a baseline Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥4 were randomized to placebo or 1 of 4 escalating doses of CC-220 (0.3 mg QOD, 0.3 mg QD, 0.6/0.3 mg alternating QD, or 0.6 mg QD 1 with a deactivating coding variant conferring significant protection against multiple immune-mediated disorders including systemic lupus erythematosus (SLE).
SAT0226 A FIRST-IN-HUMAN, STUDY OF BMS-986165, A SELECTIVE, POTENT, ALLOSTERIC SMALL MOLECULE INHIBITOR OF TYROSINE KINASE 2
Background: Tyrosine kinase 2 (Tyk2) is a member of the JAK family that phosphorylates STAT proteins downstream of the IL-12, IL-23 and the Type I interferon receptor. Tyk2 genetic variants have been linked to multiple autoimmune diseases, 1 with a deactivating coding variant conferring significant protection against multiple immune-mediated disorders including systemic lupus erythematosus (SLE).
2 Selective pharmacologic inhibition of Tyk2 has proven daunting, given the high degree of similarity among JAK catalytic domains. Using a novel approach, we have developed BMS-986165, a highly selective and potent small molecule inhibitor, which blocks receptor-mediated Tyk2 activation by stabilizing the regulatory pseudokinase domain of the protein. Lupus-like disease is strongly inhibited in NZB/W mice treated with BMS-986165. Together, these data establish Tyk2 as a highly promising therapeutic target for SLE. Objectives: We report the first evidence of safety, pharmacokinetics (PK), target engagement (TE), and pharmacodynamic activity (PD) of BMS-986165, a novel inhibitor of Tyk2. Methods: Safety, PK, TE, and PD were assessed in a randomized, double-blind, single and multiple ascending dose study of 108 (83 active: 25 placebo) healthy participants (NCT02534636). Target engagement was assessed by an ex vivo assay, IL-12 and IL-18 induced IFNγ production. Roferon-A was administered to assess in vivo pharmacodynamic effects of BMS-986165 on physiological manifestations of IFN exposure and on IFN-regulated gene (IRG) expression. Results: BMS-986165 was safe and overall well-tolerated. There were no serious adverse events and the frequency of non-serious adverse events were similar in the active (75%) and placebo (76%) groups. The most frequently reported adverse events by preferred term were headache (23% active versus 28% placebo), nausea (12% active versus 8% placebo), rash (12% active versus 8% placebo), and upper respiratory tract infection (11% active versus 12% placebo). After oral administration, BMS-986165 was rapidly absorbed and exhibited an apparent elimination half-life of 8-15 hours. Modest accumulation (1.4x-1.9x) was observed after multiple dosing. BMS-986165 inhibited IL-12/IL-18-induced IFNγ production in ex vivo assays in a dose and concentration dependent manner. Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects as many as 518 persons per 100,000 people in the United States and Europe. However, much of our current knowledge on SLE health care utilization and costs is based on analyses conducted prior to 2011, after which important treatment innovations (e.g., belimumab and, to some extent, rituximab) and health care marketplace changes occurred in the United States. Objectives: The objectives of this systematic review were to summarize the patterns of health care utilization for patients with SLE and to characterize the direct and indirect costs of SLE by disease severity in the United States. Methods: We conducted a systematic literature review of adult patients with SLE in the United States by searching PubMed and Embase for relevant articles written in English and published during January 2000-April 2016. We examined health care utilization measures including emergency department (ED) visits, hospitalizations, outpatient visits, medication use, and adherence. We restricted the analysis to observational studies, excluding case reports and commentaries. All monetary costs were converted to US 2016 $. Results: In total, 4,700 articles were screened, 388 articles were retained for full-text review, and 38 articles were selected for inclusion in this report. Across these 38 studies, mean patient ED utilization rates were 0.9-2.1 visits/year. Mean hospitalization rates were 0.4-2.6 inpatient stays/year, with 5-6 days/stay on average. Patients averaged 10-19 total physician visits/year. More than 90% of patients with SLE had ≥1 visit to a primary care provider annually. In addition, 51-71% visited rheumatologists, and 6-7% visited nephrologists. Health care resource use with respect to ED visits, hospitalization rates, inpatient length of stay, and ambulatory care was greater for patients with lupus nephritis than for patients with SLE without nephritis. Mean annual direct costs from various studies ranged between $15,171-88,445 for patients with SLE regardless of the presence of nephritis. Nearly all studies indicated that mean direct medical costs were greater for patients with moderate or severe disease ($22,300-83,000) than those with mild disease ($8,900-15,000) . Mean annual pharmacy costs ranged between $1,572-13,138, accounting for 19-23% of total direct costs, and medical costs ranged between $21,290-82,854. On average, 12-49% of patients were unemployed, and the mean number of sick days/month was 2.3 days. The range of estimates of mean total direct costs for patients with SLE overall were often
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